Year: 2019
Type: dissertation
Abstract: Pain is one of the most common medical ailments experienced worldwide, affecting roughly 20% of the global population. Despite its prevalence and decades of research, few options provide adequate pain relief and restore normal human function. The current gold standard class of drugs for acute and chronic pain is the opioid analgesics. Opioids act at the mu opioid receptor to provide robust analgesia and act as central nervous system depressants. However, their use is limited because opioids produce respiratory depression and have a high liability for abuse. The prevalence of these side effects has led to the current opioid epidemic and a call for more effective pain management therapeutics. Positive allosteric modulators and biased agonism at opioid receptors are two emerging paradigms for designing safer pain therapeutics. Positive allosteric modulation refers to ligands that bind to sites topographically distinct from the orthosteric pocket on receptors to enhance orthosteric ligand efficacy and/or affinity. In theory, these compounds could enhance activity of endogenous opioid peptides released during pain states, minimizing global receptor activation in brain regions responsible for addiction and respiratory depression. Biased agonism refers to preferential activation of one intracellular signaling pathway over another, usually G protein vs β-arrestin in the case of opioid receptors. Evidence suggests β-arrestin biased ligands produce more side effects compared to G protein biased ligands. It is well established for other receptor types, such as the muscarinic and cannabinoid systems, that allosteric modulators are capable of influencing receptor bias promoted by orthosteric ligands. However, no studies to date have examined this phenomenon at the mu opioid receptor. The work outlined in this dissertation explores the cellular consequences of allosteric modulation of opioid receptors. The results suggest that using positive allosteric modulation is a novel approach to promote signaling bias at opioid receptors. At the delta opioid receptor, the positive allosteric modulator (PAM), BMS 986187, activates the receptor in the absence of orthosteric ligand. BMS 986187 promotes signaling bias favoring G protein activation over β-arrestin recruitment via the allosteric site. This bias is engendered by lack of receptor phosphorylation and ultimately translates into decreased receptor desensitization. This work also demonstrates how BMS 986187 and a structurally unrelated PAM, BMS 986122, facilitate bias onto orthosteric ligands at the mu opioid receptor. While BMS 986187 elicits β-arrestin bias, BMS 986122 promotes G protein bias, despite both compounds acting at a shared receptor site. G protein bias is seen as favorable for mu opioid analgesics, as they produce pain relief with reduced side effects. Based on this hypothesis, BMS 986122 was chosen as a scaffold for optimization efforts through medicinal chemistry. Over 40 analogs were synthesized and tested for efficacy in enhancing orthosteric ligand functional activity. Ultimately, a lead compound was identified for future drug development efforts (CCG-258188). This drug produces a 5-fold larger effect than the original lead PAM, BMS 986122. This work sets the stage for further pharmacokinetic optimization and in vivo validation with the promise of providing a safer opioid analgesic.
Author: Stanczyk, Matthew
Institution: University of Michigan
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4289022508
